Latest NewsAktuelle News
    Home
    t2cure’s cell therapy is available through cooperating clinical centres
    t2cure cooperates with experienced partners in research and in the industry.
    t2cure's pipeline is built on clinical studies in cardiac and peripheral vascular indications
    t2cure is dedicated to the development of novel progenitor cell-based regenerative therapeutics.

    Latest News

    t2cure’s Cellular Therapeutic Receives Orphan Drug Designation 06.24.2010

    Frankfurt, Germany, June 24, 2010 – t2cure GmbH, a biopharmaceutical company developing and marketing stem cell-based regenerative therapies, announced today that the FDA has granted orphan drug designation to t2c001 for the treatment of...

    + Read more